Introduction
The acquired capability of tumor cells for tissue invasion and metastasis has been defined as a "hallmark of cancer" (1) and currently no curative therapies exist for prostate cancer (CaP) that has metastasized (2) . A chemotherapeutic agent, docetaxel, is the only approved therapy that has been shown to prolong survival among men with this condition (3); although a recent study reports improved survival among men with metastatic castration-resistant prostate cancer with use of Sipuleucel-T, an autologous active cellular immunotherapy (4) .
Despite these advances, the molecular mechanisms that underlie the process of metastasis are poorly understood.
Tumor-suppressive properties of Insulin-like Growth Factor Binding Protein (IGFBP)-3 (for review see (5)) include sequestration of the IGFs (6) and senescence association (7) . In addition, IGFBP-3 has a clear inhibitory effect on tumor cell adhesion to extracellular matrix components in the presence and absence of IGF (8) . Indeed, it was identified by microarray analysis as the most reduced transcript in CaP cells obtained through laser micro-dissection relative to neighboring normal prostatic cells (9) . We published evidence that demonstrated the anti-angiogenic and pro-apoptotic effects of IGFBP-3 on CaP in vivo (10, 11) .
Several clinical studies have shown that serum IGF-I is elevated and IGFBP-3 levels reduced in patients before the diagnosis of CaP and that increased serum levels of IGFBP-3 are associated with a decreased risk and better prognosis of CaP (12) (13) (14) . Importantly, an IGFBP-3 promoter polymorphism has been associated with increasing risk for CaP metastasis and for having tumors with a biologically more aggressive phenotype (15) .
We studied the effect of crossing mice with a genetic deletion of IGFBP-3 with mice expressing human Myc in the prostate (16) . These Myc mice reliably develop murine prostatic intraepithelial neoplasia, then locally invasive adenocarcinomas. Additionally, these tumors share molecular features with human prostate cancer. We describe an important requirement for IGFBP-3 in prostate apoptosis induced by androgen deprivation, and identify a role for IGFBP-3 as a metastasis suppression gene.
Materials and Methods

Mouse Colony, Castration, Tissue Collection, Preparation, and Necropsy
Animal experiments were approved by the Animal Research Committee (ARC) of the University of California, Los Angeles and according to NIH guidelines. IGFBP-3KO and WT mice were bred and homozygous littermates were used in the study. Male and female pups were weaned, weighed, and genotyped at 3 weeks of age and maintained on normal chow.
Ten-week-old adult male mice were castrated or sham-operated in survival surgeries and the ventral and dorsolateral prostate was removed after 2 or 3 days. Briefly, animals were anesthetized with metophane, a lateral incision was made into the scrotum and the testes ligated and removed. The incision was closed with surgical silk.
Prostates and testes were fixed and stained with H&E for morphologic analysis and quantification of apoptosis using a TUNEL strategy (see below). TUNEL staining was performed according to established procedures (10) . Apoptosis was quantitated by scoring 500 epithelial cells per field in five random fields per tissue section.
Tissues collected at necropsy were routinely fixed in 10% (v/v) phosphate-buffered formalin for 6 h and then transferred to 70% ethanol. Sections were cut from paraffin-embedded tissues and mounted on slides. Routine sections were stained with H&E.
Generation of IGFBP-3KO:Myc and WT:Myc Mice
The PB-Hi-Myc (Myc) mouse was derived at UCLA and was a kind gift of Dr. Charles Sawyers (16) . These were bred with IGFBP3KO mice, originally developed in collaboration with Lexicon Pharmaceuticals, Inc. (17) . The Myc model was generated by utilizing the probasin promoter (ARR2PB) to target the myc gene to the mouse prostate. To avoid potential genetic variations, only F3 generation of male offspring was used in this study.
Genotyping
Female Myc mice were crossed with male IGFBP-3 KO mice to produce the F1 generation. 
Biochemical Analysis
Mouse circulating IGF-1 and IGFBP-3 were measured using an in-house generated ELISA as previously described (18) . Antibody and standard for IGF-1 and IGFBP-3 were obtained from R&D Systems (Minneapolis, MN).
Tissue RNA isolation and RT-PCR
Total RNA was isolated from 80-week-old male WT:Myc prostate and lung tissue and from IGFBP-3KO:Myc prostate and lung metastasis using Trizol reagent following the manufacturer's protocol (Invitrogen, Carlsbad, CA) followed by purification using the Qiagen containing 10% fetal bovine serum plus 100 μg/ml penicillin and 100 μg/ml streptomycin.
After washing with PBS 3 times, the tumor tissues were cut into 1 mm Androgen Receptor (AR) (Invitrogen, Carlsbad, CA); and β-actin (Sigma, St. Louis, MO).
Membranes were incubated with horseradish peroxidase-linked secondary antibodies, washed and antigen-antibody complexes were visualized using enhanced chemiluminescence detection (Millipore, Billerica, MA).
In vitro invasion Assay
The ability of prostate cancer cells to invade was examined in 24- in a humidified incubator at 37℃, and colonies were stained with 0.5 ml of 0.01% crystal violet solution for 10 min and counted using a dissecting microscope (50x magnification) for each triplicate sample. The average values are presented as mean ± SD.
In vitro cell growth kinetics
To determine cell growth kinetics, cells were grown in DMEM medium containing 10% fetal bovine serum and 0.1 nM R1881 (PerkinElmer Life Sciences, Boston, MA) in 96-well dishes at an initial density of 2,000 cells per well. Media was changed every three days. On days 1 through 5, cells were incubated with 10 μl of Cell Counting Kit-8 (CCK-8, Dojindo, Japan) for 3 hours, then absorbance at 450 nm was measured using an ELISA plate reader (Spectra MAX 190, Molecular Devices, Sunnyvale, CA).
Gene expression microarray analysis
Whole-genome expression analysis was performed with the Affymetrix Mouse Gene Array clustered with the following parameters: Clustering Algorithm: Hierarchical; Similarity Measure: Euclidean; Linkage Rule: Centroid. We used the DAVID program (19) to identify functional groups represented in these lists. Gene lists were tested for significant pathways using the MetaCore pathway web application by GeneGO, Inc. (St. Joseph, MI).
Statistics
All in vitro experiments were repeated at least three times. Means ± SD are shown.
Statistical analyses were done using T-test, ANOVA, or Fisher's exact tests using InStat as indicated (GraphPad, San Diego, CA). Differences were considered statistically significant when *P < 0.05 and when **P < 0.005.
Results
IGFBP-3 is required for androgen deprivation-induced apoptosis
Multiple genes, including IGFBP-3 (20, 21) are upregulated in the prostate in response to androgen-deprivation; however, many of them (including Clusterin (22) , and Bax (23)) have been shown not to be essential to prostatic apoptosis utilizing knockout mouse models. To assess the functional contribution of IGFBP-3 to prostate apoptosis in response to androgendeprivation we utilized the IGFBP-3 knockout (KO) mouse (17) . Ten-week-old male wild type (WT) mice and IGFBP-3 KO mice were surgically castrated and prostates were harvested after 48 and 72 hours. The histological appearance of both testes and prostates from IGFBP-3 KO mice pre-castration did not differ from their control littermates at baseline as determined by H&E staining (data not shown). As expected, WT mouse prostates showed a dramatic 6-fold increase in the number of TUNEL-positive nuclei at 48 hours post castration ( Figure 1A ).
However, IGFBP-3 KO mice prostates failed to show any significant increase in TUNEL staining at 48 hours. By 72 hours TUNEL staining returned to near baseline levels in WT 
in the KO mouse and remained unchanged in WT mice post-castration ( Figure   1B ). Whereas data are conflicting on whether apoptosis secondary to androgen ablation is modified in p53 deficient mice (24, 25) , we have now shown that IGFBP-3, which is activated downstream of p53 (26) , is required for this process.
We did not observe spontaneous prostate tumor development with aging in IGFBP3KO mice. However, the incidence of splenic lymphomas in female IGFBP3KO mice was 23%; no splenic lymphomas were observed in WT mice (data not shown). We measured serum IGF-1 levels in these mice and found that it was decreased by more than 40% in the IGFBP-3KO:Myc mice when compared with controls ( Figure 2B ), thus providing a possible mechanism for the decreased cancer observed in the knockout animals.
Paradoxical progression of
This finding correlates well with clinical studies showing serum IGF-1 levels to be an important determinant of early CaP (12, 27) in humans and mice (28, 29) . By 24 weeks of age, well-differentiated cancer was observed in all mice irrespective of IGFBP-3 status (Supp. Figure 1A) . By 80 weeks of age, prostate carcinoma was observed in all mice; however, tumors tended to be bigger in IGFBP3KO:Myc mice (Supp. Figure 1B) with some very large tumors in IGFBP3KO:Myc mice, 20% of which weighed more than 4g (Supp. Figure 1C) . 
Increased metastasis in IGFBP-3KO:Myc mice
When IGFBP-3KO:Myc mice were necropsied at 80 weeks of age, prostate tumors tended to be larger in the IGFBP-3KO:Myc mice when compared with WT (Supp. Figure 1B) . In addition, we identified lung metastases in 55% of IGFBP-3KO:Myc mice, while none of the WT:Myc mice exhibited any metastases ( Figure 3A, 3B ). This is a remarkable finding, as metastases in the Myc model of prostate cancer have not been described to date, and suggests a major anti-tumorigenic role for endogenous IGFBP-3 as a metastasis suppressor.
We characterized the presumptive lung metastases by immunohistochemical staining for Clara Cell 10 (CC10) protein, a marker of bronchiolar epithelial cells (30) . CC10 is expressed in the lung in non-ciliated airway epithelial cells and is not expressed in prostate cells. Most primary lung adenomas and adenocarcinomas are of Clara cell origin.
As shown in Figure 4A , normal lung parenchyma stains positive for CC10, and the lung nodule does not, demonstrating that the observed lung nodules are not of lung origin. To determine the properties of these established cell lines, we performed Western blot analysis using antibodies corresponding to phenotypic markers in the prostate epithelium. As shown in Figure Figure 6C ). Thus taken together, these data support a role for IGFBP-3 in metastasis suppression in prostate cancer.
Differential Gene Expression in WT:Myc and IGFBP-3KO:Myc primary prostate tumor cell lines
Differential gene expression was examined using microarray analysis. Microarray analysis (28,815 genes) revealed that 462 genes were upregulated and 760 genes were downregulated (fold-change > 3.0; P < 0.05) (see Supplemental Table 1 for complete list; Figure 7A ). Gene lists were tested for significant pathways using the MetaCore pathway web application by GeneGO, Inc. The most significant pathway maps were ranked by the negative log of the calculated hypergeometric p value. Genes differentially expressed fell into many different pathways but the two most significant pathways include cell adhesion and extracellular matrix remodeling, and development/regulation of epithelial-to-mesenchymal (EMT) transition, important pathways in the development of cancer metastasis ( Figure 7B ). SM22 (also known as Transgelin) was down-regulated 60-fold in IGFBP-3KO:Myc cells compared to WT:Myc cells in the array. A significant decrease in SM22 expression was confirmed by immunoblot ( Figure 7C ). SM22 is an actin cross-linking protein and functions as a tumor suppressor. Its expression in prostate cancer is decreased (36) . 
The tumor-suppressive properties of IGFBP-3 have been intensely studied in our laboratory and by others in vitro and include IGF sequestration (6); mediation of anti-growth signals (37, 38); induction of cancer cell apoptosis (39); senescence-association (7); and its effects as an anti-angiogenic agent (11) . Molecular mechanisms underlying these effects in CaP cells include rapid cellular internalization via Caveolin-1 binding and nuclear localization (40, 41) ; and activation of the intrinsic apoptosis pathway via association with the nuclear receptors RXRα and Nur77 and nuclear export with subsequent mitochondrial translocation (39, 42, 43) . Importantly, we have established an important physiologic role for IGFBP-3 in apoptosis induced by androgen-deprivation.
Recent studies have hinted at a role for IGFBP-3 as a metastasis suppression gene. In a study of ovarian epithelial cancer (OEC) cell with invasion-related sublines, microarray analysis revealed IGFBP-3 to be one of the most suppressed genes in the most invasive subline P4. Re-expression of IGFBP-3 in P4 effectively inhibited cell migration, invasion and metastasis, but did not affect cell proliferation. In patients with EC tumors, low IGFBP-3 expression correlated clinically with higher tumor grade, advanced stage and poor survival (44) . Moreover, in non-small cell lung cancer (NSCLC) cells, non-cytotoxic doses of adenoviral or recombinant IGFBP-3 significantly decreased the migration, invasion, and metastatic potential of H1299 and A549 NSCLC cells in vitro and in vivo (45) . Furthermore, in patients with previously untreated metastatic colorectal cancer, higher baseline circulating levels of IGFBP-3 were associated with a significantly greater response rate to chemotherapy and a longer time to tumor progression and overall survival, even after adjusting for other potential predictors of patient outcome (46) .
In men with prostate cancer, plasma IGFBP-3 levels were lowest in patients with bone metastases with lower preoperative IGFBP-3 levels and biopsy Gleason score being (14) . Importantly, an A/C polymorphism at position -202 in the promoter region of IGFBP-3 was correlated to increased risk of metastatic disease in a Japanese study, with those men with CC and AC genotype having a significantly increased risk of metastatic disease (stage D) those with AA genotype. Therefore, the authors concluded that the presence of the C allele may cumulatively increase the risk for tumor metastasis and for having tumors with a biologically more aggressive phenotype (15) .
In genetic mouse models of prostate cancer, many are aggressive and metastasize at an early age. These include: prostate PTEN deletion (12-29 weeks; (47) 
